Title : Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

Pub. Date : 2008 Feb

PMID : 17597710






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In CYP2C9*3 allele carriers using tolbutamide, the prescribed dose was lower compared to patients with the wild-type CYP2C9 genotype. Tolbutamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 In CYP2C9*3 allele carriers using tolbutamide, the prescribed dose was lower compared to patients with the wild-type CYP2C9 genotype. Tolbutamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 In CYP2C9*3 allele carriers, the mean decrease in fasting serum glucose levels after the start of tolbutamide therapy was larger than in patients with the wild-type genotype, although not statistically significant. Tolbutamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens
4 Patients with diabetes mellitus who are carriers of a CYP2C9*3 allele require lower doses of tolbutamide to regulate their serum glucose levels compared to patients with the wild-type genotype. Tolbutamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens